Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 01/13 10:00:14 pm
62.34 USD   +0.21%
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12 DOW MOVERS : Msft, mrk
01/12DJHealth Stocks Fall as Trump Slams Industry -- WSJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : FDA Denies Merck Request to Block Generic Form of Nasonex

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/19/2012 | 08:47pm CET
   By Peter Loftus 
 

Merck & Co. (MRK) lost another round in its effort to block a competing generic copy of its Nasonex allergy nasal spray from entering the U.S. market.

The U.S. Food and Drug Administration this month denied Merck's petition asking the agency not to approve applications by generic drug makers to sell certain proposed generic forms of Nasonex. Merck, of Whitehouse Station, N.J., had argued the FDA shouldn't approve any proposed generic copy that has a different formulation than Nasonex.

The FDA denial of Merck's petition follows a federal court ruling earlier this year finding that Apotex Corp.'s proposed generic version of Nasonex doesn't violate a Merck patent for the drug. Merck has appealed that patent ruling.

Both developments remove some obstacles to the market entry of competing generic versions of Nasonex before patent protection expires in 2018, which would hurt sales of the branded drug. The drug, which Merck obtained in its 2009 purchase of Schering-Plough, generated $960 million in sales for the first nine months of 2012.

Canada's Apotex wants to sell a generic version of Nasonex that is slightly different from the original. The proposed Apotex product would have the same active ingredient, mometasone furoate, but in a non-water formulation, whereas Merck's product has a water component.

In 2009, Merck filed a patent-infringement lawsuit against Apotex in response to Apotex's application to market the generic product. Apotex argued that its proposed product wouldn't infringe upon Merck's patent because it would be a non-water formulation of mometasone furoate.

Following an April trial in federal court in Trenton, N.J., U.S. District Judge Peter G. Sheridan in June ruled that Apotex's proposed product wouldn't infringe upon the Merck patent, though the judge upheld the patent's validity. Merck has appealed the ruling.

In July, Merck filed a so-called citizen petition asking the FDA to refrain from approving any application for a non-water version of Nasonex that relies upon clinical data for the original drug. Merck argued that the non-water version couldn't be considered as the pharmaceutical equivalent to Nasonex because there would likely be differences in how they are absorbed in the body.

Lawyers for Apotex objected to Merck's request in a November comment letter to FDA, saying there was established precedent for the agency to approve generic versions of branded drugs that contain slightly different forms of the same active ingredient.

In a Dec. 7 letter, the FDA denied Merck's petition, saying that a non-water form of mometasone could potentially be considered pharmaceutically and therapeutically equivalent to the water-based Nasonex, assuming other requirements are met.

"We were disappointed with the decision on the citizen petition," said Merck spokesman Ronald Rogers.

The FDA denial of Merck's petition doesn't amount to approval of Apotex's generic product; that review is pending.

Apotex spokesman Steve Giuli declined to comment.

Merck shares declined 38 cents to $43.85 Wednesday.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12 MERCK : Reports from Merck & Company Add New Data to Findings in Genetic Epidemi..
01/12 REPORTS SUMMARIZE ORGANIC RESEARCH F : Application to the...
01/12 STUDIES FROM MERCK & COMPANY YIELD N : potential...
01/12 DOW MOVERS : Msft, mrk
01/12DJHealth Stocks Fall as Trump Slams Industry -- WSJ
01/11 Merck and United jump while Signet and SuperValu fall
01/11 S&P 500 MOVERS : Nem, mrk
01/11 DOW MOVERS : Utx, mrk
01/10 MERCK : Receives FDA Acceptance of Supplemental Biologics License Application fo..
More news
Sector news : Pharmaceuticals - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/13DJLONDON MARKETS : FTSE 100 Continues Record Run, Rising For 14th Day In A Row
01/13 FTSE hits record highs, extends historic winning streak
01/12DJCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
01/12 Investors in big pharma, biotech look to ride out Trump storm
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/16 PFIZER : 2 Risks Every Shareholder Should Be Aware Of
01/13 SANOFI : Key Threats In 2017 And Beyond
01/13 BIOTECH FORUM DAILY DIGEST : Trump Dings Biotech, What Now For Conatus Pharmaceu..
01/13 BIOTECHS : What The 'Trump Dump' And CVS's EpiPen Move May Mean
01/13 Dissecting The Stockpickers
Advertisement
Financials ($)
Sales 2016 39 936 M
EBIT 2016 13 690 M
Net income 2016 5 900 M
Debt 2016 3 978 M
Yield 2016 2,98%
P/E ratio 2016 30,08
P/E ratio 2017 17,91
EV / Sales 2016 4,40x
EV / Sales 2017 4,37x
Capitalization 171 880 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,2 $
Spread / Average Target 9,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.5.89%171 880
JOHNSON & JOHNSON-0.53%311 773
ROCHE HOLDING LTD.2.75%204 641
PFIZER INC.0.12%197 343
NOVARTIS AG-1.48%189 749
SANOFI1.52%107 323
More Results